author_facet Fruschelli, M.
Fazio, S.
Capozzoli, M.
Chimenti, G.
Hadjistilianou, T.
Sicuranza, A.
Aprile, L.
Puccetti, L.
Fruschelli, M.
Fazio, S.
Capozzoli, M.
Chimenti, G.
Hadjistilianou, T.
Sicuranza, A.
Aprile, L.
Puccetti, L.
author Fruschelli, M.
Fazio, S.
Capozzoli, M.
Chimenti, G.
Hadjistilianou, T.
Sicuranza, A.
Aprile, L.
Puccetti, L.
spellingShingle Fruschelli, M.
Fazio, S.
Capozzoli, M.
Chimenti, G.
Hadjistilianou, T.
Sicuranza, A.
Aprile, L.
Puccetti, L.
Acta Ophthalmologica
Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
Ophthalmology
General Medicine
author_sort fruschelli, m.
spelling Fruschelli, M. Fazio, S. Capozzoli, M. Chimenti, G. Hadjistilianou, T. Sicuranza, A. Aprile, L. Puccetti, L. 1755-375X 1755-3768 Wiley Ophthalmology General Medicine http://dx.doi.org/10.1111/j.1755-3768.2016.0542 <jats:sec><jats:title>Purpose</jats:title><jats:p>It is still a matter of debate whether anticoagulant or antiplatelet therapy are useful for the prevention of retinal vein occlusions. In some cases, patients who are already under antiplatelet or anticoagulant therapy still develop retinal venous diseases. We analyzed the prevalence of RVO in patients treated yet with warfarin or aspirin for other clinical indications.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>64 patients (30 CRVO and 34 BRVO) treated with warfarin for atrial fibrillation (<jats:italic>n</jats:italic> = 11) or aspirin for carotid stenosis (<jats:italic>n</jats:italic> = 53) were observed. Multivariate analysis was employed to detect any putative relation among treatments and CRVO or BRVO.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The whole cohort analysis showed that aspirin was less effective than warfarin for prevention of RVO (H.R. 2.4, 95% C.I. 1.9–3.2 p &lt; 0.01); 9 BRVO and 2 CRVO were in patients treated with warfarin whereas 25 BRVO and 28 CRVO in aspirin treated subjects. The confirmation test showed an H.R. of 2.1 (1.6–3.1 95% C.I.) p &lt; 0.01, for the association between aspirin treatment and CRVO.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Such retrospective data indicate that aspirin could be less effective in RVO and particularly CRVO prevention with respect to anticoagulants. Planned large prospective observational studies are needed to study the efficacy of such treatments in RVO prevention and treatment. Our data could fit well with the previous observation that specific pro‐coagulative state as suggested by increased thrombin generation is a pattern of CRVO with respect to BRVO.</jats:p></jats:sec> Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention Acta Ophthalmologica
doi_str_mv 10.1111/j.1755-3768.2016.0542
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE3NTUtMzc2OC4yMDE2LjA1NDI
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE3NTUtMzc2OC4yMDE2LjA1NDI
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint Wiley, 2016
imprint_str_mv Wiley, 2016
issn 1755-375X
1755-3768
issn_str_mv 1755-375X
1755-3768
language English
mega_collection Wiley (CrossRef)
match_str fruschelli2016incidenceofretinalveinocclusionsrvoinpatientstreatedwithoralanticoagulantsorantiplateletdrugsforcardioembolicoratherothromboticprevention
publishDateSort 2016
publisher Wiley
recordtype ai
record_format ai
series Acta Ophthalmologica
source_id 49
title Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_unstemmed Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_full Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_fullStr Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_full_unstemmed Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_short Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_sort incidence of retinal vein occlusions (rvo) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
topic Ophthalmology
General Medicine
url http://dx.doi.org/10.1111/j.1755-3768.2016.0542
publishDate 2016
physical
description <jats:sec><jats:title>Purpose</jats:title><jats:p>It is still a matter of debate whether anticoagulant or antiplatelet therapy are useful for the prevention of retinal vein occlusions. In some cases, patients who are already under antiplatelet or anticoagulant therapy still develop retinal venous diseases. We analyzed the prevalence of RVO in patients treated yet with warfarin or aspirin for other clinical indications.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>64 patients (30 CRVO and 34 BRVO) treated with warfarin for atrial fibrillation (<jats:italic>n</jats:italic> = 11) or aspirin for carotid stenosis (<jats:italic>n</jats:italic> = 53) were observed. Multivariate analysis was employed to detect any putative relation among treatments and CRVO or BRVO.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The whole cohort analysis showed that aspirin was less effective than warfarin for prevention of RVO (H.R. 2.4, 95% C.I. 1.9–3.2 p &lt; 0.01); 9 BRVO and 2 CRVO were in patients treated with warfarin whereas 25 BRVO and 28 CRVO in aspirin treated subjects. The confirmation test showed an H.R. of 2.1 (1.6–3.1 95% C.I.) p &lt; 0.01, for the association between aspirin treatment and CRVO.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Such retrospective data indicate that aspirin could be less effective in RVO and particularly CRVO prevention with respect to anticoagulants. Planned large prospective observational studies are needed to study the efficacy of such treatments in RVO prevention and treatment. Our data could fit well with the previous observation that specific pro‐coagulative state as suggested by increased thrombin generation is a pattern of CRVO with respect to BRVO.</jats:p></jats:sec>
container_issue S256
container_start_page 0
container_title Acta Ophthalmologica
container_volume 94
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792333967434711040
geogr_code not assigned
last_indexed 2024-03-01T14:21:10.426Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Incidence+of+retinal+vein+occlusions+%28RVO%29+in+patients+treated+with+oral+anticoagulants+or+antiplatelet+drugs+for+cardioembolic+or+atherothrombotic+prevention&rft.date=2016-10-01&genre=article&issn=1755-3768&volume=94&issue=S256&jtitle=Acta+Ophthalmologica&atitle=Incidence+of+retinal+vein+occlusions+%28RVO%29+in+patients+treated+with+oral+anticoagulants+or+antiplatelet+drugs+for+cardioembolic+or+atherothrombotic+prevention&aulast=Puccetti&aufirst=L.&rft_id=info%3Adoi%2F10.1111%2Fj.1755-3768.2016.0542&rft.language%5B0%5D=eng
SOLR
_version_ 1792333967434711040
author Fruschelli, M., Fazio, S., Capozzoli, M., Chimenti, G., Hadjistilianou, T., Sicuranza, A., Aprile, L., Puccetti, L.
author_facet Fruschelli, M., Fazio, S., Capozzoli, M., Chimenti, G., Hadjistilianou, T., Sicuranza, A., Aprile, L., Puccetti, L., Fruschelli, M., Fazio, S., Capozzoli, M., Chimenti, G., Hadjistilianou, T., Sicuranza, A., Aprile, L., Puccetti, L.
author_sort fruschelli, m.
container_issue S256
container_start_page 0
container_title Acta Ophthalmologica
container_volume 94
description <jats:sec><jats:title>Purpose</jats:title><jats:p>It is still a matter of debate whether anticoagulant or antiplatelet therapy are useful for the prevention of retinal vein occlusions. In some cases, patients who are already under antiplatelet or anticoagulant therapy still develop retinal venous diseases. We analyzed the prevalence of RVO in patients treated yet with warfarin or aspirin for other clinical indications.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>64 patients (30 CRVO and 34 BRVO) treated with warfarin for atrial fibrillation (<jats:italic>n</jats:italic> = 11) or aspirin for carotid stenosis (<jats:italic>n</jats:italic> = 53) were observed. Multivariate analysis was employed to detect any putative relation among treatments and CRVO or BRVO.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The whole cohort analysis showed that aspirin was less effective than warfarin for prevention of RVO (H.R. 2.4, 95% C.I. 1.9–3.2 p &lt; 0.01); 9 BRVO and 2 CRVO were in patients treated with warfarin whereas 25 BRVO and 28 CRVO in aspirin treated subjects. The confirmation test showed an H.R. of 2.1 (1.6–3.1 95% C.I.) p &lt; 0.01, for the association between aspirin treatment and CRVO.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Such retrospective data indicate that aspirin could be less effective in RVO and particularly CRVO prevention with respect to anticoagulants. Planned large prospective observational studies are needed to study the efficacy of such treatments in RVO prevention and treatment. Our data could fit well with the previous observation that specific pro‐coagulative state as suggested by increased thrombin generation is a pattern of CRVO with respect to BRVO.</jats:p></jats:sec>
doi_str_mv 10.1111/j.1755-3768.2016.0542
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE3NTUtMzc2OC4yMDE2LjA1NDI
imprint Wiley, 2016
imprint_str_mv Wiley, 2016
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 1755-375X, 1755-3768
issn_str_mv 1755-375X, 1755-3768
language English
last_indexed 2024-03-01T14:21:10.426Z
match_str fruschelli2016incidenceofretinalveinocclusionsrvoinpatientstreatedwithoralanticoagulantsorantiplateletdrugsforcardioembolicoratherothromboticprevention
mega_collection Wiley (CrossRef)
physical
publishDate 2016
publishDateSort 2016
publisher Wiley
record_format ai
recordtype ai
series Acta Ophthalmologica
source_id 49
spelling Fruschelli, M. Fazio, S. Capozzoli, M. Chimenti, G. Hadjistilianou, T. Sicuranza, A. Aprile, L. Puccetti, L. 1755-375X 1755-3768 Wiley Ophthalmology General Medicine http://dx.doi.org/10.1111/j.1755-3768.2016.0542 <jats:sec><jats:title>Purpose</jats:title><jats:p>It is still a matter of debate whether anticoagulant or antiplatelet therapy are useful for the prevention of retinal vein occlusions. In some cases, patients who are already under antiplatelet or anticoagulant therapy still develop retinal venous diseases. We analyzed the prevalence of RVO in patients treated yet with warfarin or aspirin for other clinical indications.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>64 patients (30 CRVO and 34 BRVO) treated with warfarin for atrial fibrillation (<jats:italic>n</jats:italic> = 11) or aspirin for carotid stenosis (<jats:italic>n</jats:italic> = 53) were observed. Multivariate analysis was employed to detect any putative relation among treatments and CRVO or BRVO.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The whole cohort analysis showed that aspirin was less effective than warfarin for prevention of RVO (H.R. 2.4, 95% C.I. 1.9–3.2 p &lt; 0.01); 9 BRVO and 2 CRVO were in patients treated with warfarin whereas 25 BRVO and 28 CRVO in aspirin treated subjects. The confirmation test showed an H.R. of 2.1 (1.6–3.1 95% C.I.) p &lt; 0.01, for the association between aspirin treatment and CRVO.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Such retrospective data indicate that aspirin could be less effective in RVO and particularly CRVO prevention with respect to anticoagulants. Planned large prospective observational studies are needed to study the efficacy of such treatments in RVO prevention and treatment. Our data could fit well with the previous observation that specific pro‐coagulative state as suggested by increased thrombin generation is a pattern of CRVO with respect to BRVO.</jats:p></jats:sec> Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention Acta Ophthalmologica
spellingShingle Fruschelli, M., Fazio, S., Capozzoli, M., Chimenti, G., Hadjistilianou, T., Sicuranza, A., Aprile, L., Puccetti, L., Acta Ophthalmologica, Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention, Ophthalmology, General Medicine
title Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_full Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_fullStr Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_full_unstemmed Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_short Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_sort incidence of retinal vein occlusions (rvo) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
title_unstemmed Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention
topic Ophthalmology, General Medicine
url http://dx.doi.org/10.1111/j.1755-3768.2016.0542